These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20167657

  • 1. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.
    Bietrix F, Lombardo E, van Roomen CP, Ottenhoff R, Vos M, Rensen PC, Verhoeven AJ, Aerts JM, Groen AK.
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):931-7. PubMed ID: 20167657
    [Abstract] [Full Text] [Related]

  • 2. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells.
    Bijl N, Scheij S, Houten S, Boot RG, Groen AK, Aerts JM.
    J Pharmacol Exp Ther; 2008 Sep; 326(3):849-55. PubMed ID: 18550691
    [Abstract] [Full Text] [Related]

  • 3. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice.
    Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK.
    Hepatology; 2009 Feb; 49(2):637-45. PubMed ID: 19072830
    [Abstract] [Full Text] [Related]

  • 4. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
    Langeveld M, van den Berg SA, Bijl N, Bijland S, van Roomen CP, Houben-Weerts JH, Ottenhoff R, Houten SM, van Dijk KW, Romijn JA, Groen AK, Aerts JM, Voshol PJ.
    Metabolism; 2012 Jan; 61(1):99-107. PubMed ID: 21816446
    [Abstract] [Full Text] [Related]

  • 5. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
    Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M.
    Hepatology; 2009 Nov; 50(5):1431-41. PubMed ID: 19731235
    [Abstract] [Full Text] [Related]

  • 6. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
    Bousette N, D'Orleans-Juste P, Kiss RS, You Z, Genest J, Al-Ramli W, Qureshi ST, Gramolini A, Behm D, Ohlstein EH, Harrison SM, Douglas SA, Giaid A.
    Circ Res; 2009 Sep 25; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
    Shen C, Bullens D, Kasran A, Maerten P, Boon L, Aerts JM, Van Assche G, Geboes K, Rutgeerts P, Ceuppens JL.
    Int Immunopharmacol; 2004 Jul 25; 4(7):939-51. PubMed ID: 15182733
    [Abstract] [Full Text] [Related]

  • 8. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
    Shi W, Wang X, Wong J, Hedrick CC, Wong H, Castellani LW, Lusis AJ.
    Biochem Biophys Res Commun; 2004 Apr 23; 317(1):223-9. PubMed ID: 15047172
    [Abstract] [Full Text] [Related]

  • 9. Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.
    Lombardo E, van Roomen CP, van Puijvelde GH, Ottenhoff R, van Eijk M, Aten J, Kuiper J, Overkleeft HS, Groen AK, Verhoeven AJ, Aerts JM, Bietrix F.
    PLoS One; 2012 Apr 23; 7(10):e38520. PubMed ID: 23056165
    [Abstract] [Full Text] [Related]

  • 10. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.
    Zhao Y, Su B, Jacobs RL, Kennedy B, Francis GA, Waddington E, Brosnan JT, Vance JE, Vance DE.
    Arterioscler Thromb Vasc Biol; 2009 Sep 23; 29(9):1349-55. PubMed ID: 19520976
    [Abstract] [Full Text] [Related]

  • 11. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Chiwata T, Aragane K, Fujinami K, Kojima K, Ishibashi S, Yamada N, Kusunoki J.
    Br J Pharmacol; 2001 Aug 23; 133(7):1005-12. PubMed ID: 11487509
    [Abstract] [Full Text] [Related]

  • 12. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
    Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.
    Arterioscler Thromb Vasc Biol; 2010 Apr 23; 30(4):742-8. PubMed ID: 20110573
    [Abstract] [Full Text] [Related]

  • 13. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K, Nishizawa T, Abe K, Wakabayashi K, Oda T, Inaba T, Amemiya Y.
    J Pharm Pharmacol; 2006 Dec 23; 58(12):1629-38. PubMed ID: 17331327
    [Abstract] [Full Text] [Related]

  • 14. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH.
    Arzneimittelforschung; 1998 Apr 23; 48(4):396-402. PubMed ID: 9608883
    [Abstract] [Full Text] [Related]

  • 15. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC.
    Arterioscler Thromb Vasc Biol; 2006 Nov 23; 26(11):2552-9. PubMed ID: 16946130
    [Abstract] [Full Text] [Related]

  • 16. Hepatic glycosphingolipid deficiency and liver function in mice.
    Jennemann R, Rothermel U, Wang S, Sandhoff R, Kaden S, Out R, van Berkel TJ, Aerts JM, Ghauharali K, Sticht C, Gröne HJ.
    Hepatology; 2010 May 23; 51(5):1799-809. PubMed ID: 20432257
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.
    Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS.
    Diabetes; 2007 May 23; 56(5):1341-9. PubMed ID: 17287460
    [Abstract] [Full Text] [Related]

  • 18. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Sberna AL, Assem M, Xiao R, Ayers S, Gautier T, Guiu B, Deckert V, Chevriaux A, Grober J, Le Guern N, Pais de Barros JP, Moore DD, Lagrost L, Masson D.
    Arterioscler Thromb Vasc Biol; 2011 Oct 23; 31(10):2232-9. PubMed ID: 21778422
    [Abstract] [Full Text] [Related]

  • 19. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
    Moghadasian MH, Nguyen LB, Shefer S, Salen G, Batta AK, Frohlich JJ.
    Metabolism; 2001 Jun 23; 50(6):708-14. PubMed ID: 11398149
    [Abstract] [Full Text] [Related]

  • 20. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, Baumann G, Stangl V, Stangl K, Ludwig A.
    Arterioscler Thromb Vasc Biol; 2012 Jun 23; 32(6):1418-26. PubMed ID: 22516063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.